Moderna is set to report its latest quarterly earnings on Thursday, April 30th, with a consensus estimate EPS of -2.28.
Today, Moderna's stock price stands at $47.45, showing a decrease of $1.25 (-2.57%) from the previous close. Noteworthy is the trading volume, reaching $855,898, which is 10.24% above the average.
Over the past three days, Moderna has experienced a price streak, with a notable drop of $8.15 (-14.66%) from $55.6.
In the latest quarterly earnings report on Thursday, February 12th, Moderna reported an EPS of -2.6.
Modern's cash flow depicts a positive trend with a net change in cash of $1.46 billion, reaching a total of $2.60 billion at the end of the period.
The company's income statement reflects challenges, with a net income of -$826 million and an EPS of -$2.11.
Key financial ratios show mixed results, with a negative net profit margin of -121.83% and a price-to-earnings ratio of -3.5.
Modern's balance sheet reveals a strong financial position, with total assets amounting to $12.34 billion and total liabilities at $3.69 billion.
This comprehensive financial report provides insights into Moderna's current financial standing and performance trends.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.